5-[123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model

Janina Baranowska-Kortylewicz, G. Mike Makrigiorgos, Annick D. Van Den Abbeele, Robert M. Berman, S. James Adelstein, Amin I. Kassis

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The extreme biological toxicity of Auger emitters is caused by the decay-associated, highly localized deposition of energy. The antineoplastic capability of an Auger-electron emitter, iodine-123, incorporated into the thymidine analog, 5-iodo-2′-deoxyuridine (IUdR) was evaluated in an intraperitoneal (ig.) murine ovarian tumor (MOT) in female C3HeB/Fej mice. Total doses of 0.37 to 8.88 MBq (10-240 μCi) 123IUdR were administered i.p. in five equally divided fractions at 24, 28, 32, 36, and 40 hr after the i.p. inoculation of 0.5 to 1.6 × 106 tumor cells per mouse. Control tumor-bearing animals were injected with identical volumes of saline at 4-hr intervals. Biodistribution studies demonstrated a distinct and localized uptake of 123IUdR in the MOT cells (1 % of the injected dose was associated with MOT cells 24 hr after the last injection), whereas in animals without tumor there was no radioactivity associated with the peritoneal cells. Analogous results were obtained from scintigraphic images where the focal area of abdominal activity persisted only in MOT-bearing mice while it cleared from the abdomen of the controls. The 50% survival (median survival) of the control group was 19 days for an inoculum of 1.6 × 106 MOT cells per animal, whereas the median survival of MOT-bearing animals treated with 123IUdR increased by 11 days for the highest administered dose (8.88 MBq, 240 μCi) and resulted in a 20% absolute survival at 7 weeks. Statistically significant absolute survival prolongation was found with all of the total administered doses. The prolongation of both median and absolute survival time of the tumor-bearing animals treated with 123IUdR conclusively indicates the substantial antineoplastic activity of the Auger-electron emitter iodine-123.

Original languageEnglish (US)
Pages (from-to)1541-1551
Number of pages11
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume21
Issue number6
DOIs
StatePublished - Jan 1 1991

Fingerprint

Deoxyuridine
Ascites
radiation therapy
Radiotherapy
tumors
animals
Neoplasms
mice
prolongation
dosage
emitters
cells
Iodine
Antineoplastic Agents
iodine
inoculum
Electrons
Idoxuridine
thymidine
abdomen

Keywords

  • 5-Iodo-2′-deoxyuridine
  • Auger-electron emitters
  • Biodistribution
  • Dosimetry
  • Iodine radioisotopes
  • Murine ovarian tumor
  • Radiotherapy
  • Scintigraphy

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

5-[123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. / Baranowska-Kortylewicz, Janina; Makrigiorgos, G. Mike; Van Den Abbeele, Annick D.; Berman, Robert M.; Adelstein, S. James; Kassis, Amin I.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 21, No. 6, 01.01.1991, p. 1541-1551.

Research output: Contribution to journalArticle

Baranowska-Kortylewicz, Janina ; Makrigiorgos, G. Mike ; Van Den Abbeele, Annick D. ; Berman, Robert M. ; Adelstein, S. James ; Kassis, Amin I. / 5-[123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. In: International Journal of Radiation Oncology, Biology, Physics. 1991 ; Vol. 21, No. 6. pp. 1541-1551.
@article{a9988d61b28e493486206d88c9331408,
title = "5-[123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model",
abstract = "The extreme biological toxicity of Auger emitters is caused by the decay-associated, highly localized deposition of energy. The antineoplastic capability of an Auger-electron emitter, iodine-123, incorporated into the thymidine analog, 5-iodo-2′-deoxyuridine (IUdR) was evaluated in an intraperitoneal (ig.) murine ovarian tumor (MOT) in female C3HeB/Fej mice. Total doses of 0.37 to 8.88 MBq (10-240 μCi) 123IUdR were administered i.p. in five equally divided fractions at 24, 28, 32, 36, and 40 hr after the i.p. inoculation of 0.5 to 1.6 × 106 tumor cells per mouse. Control tumor-bearing animals were injected with identical volumes of saline at 4-hr intervals. Biodistribution studies demonstrated a distinct and localized uptake of 123IUdR in the MOT cells (1 {\%} of the injected dose was associated with MOT cells 24 hr after the last injection), whereas in animals without tumor there was no radioactivity associated with the peritoneal cells. Analogous results were obtained from scintigraphic images where the focal area of abdominal activity persisted only in MOT-bearing mice while it cleared from the abdomen of the controls. The 50{\%} survival (median survival) of the control group was 19 days for an inoculum of 1.6 × 106 MOT cells per animal, whereas the median survival of MOT-bearing animals treated with 123IUdR increased by 11 days for the highest administered dose (8.88 MBq, 240 μCi) and resulted in a 20{\%} absolute survival at 7 weeks. Statistically significant absolute survival prolongation was found with all of the total administered doses. The prolongation of both median and absolute survival time of the tumor-bearing animals treated with 123IUdR conclusively indicates the substantial antineoplastic activity of the Auger-electron emitter iodine-123.",
keywords = "5-Iodo-2′-deoxyuridine, Auger-electron emitters, Biodistribution, Dosimetry, Iodine radioisotopes, Murine ovarian tumor, Radiotherapy, Scintigraphy",
author = "Janina Baranowska-Kortylewicz and Makrigiorgos, {G. Mike} and {Van Den Abbeele}, {Annick D.} and Berman, {Robert M.} and Adelstein, {S. James} and Kassis, {Amin I.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/0360-3016(91)90331-W",
language = "English (US)",
volume = "21",
pages = "1541--1551",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - 5-[123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model

AU - Baranowska-Kortylewicz, Janina

AU - Makrigiorgos, G. Mike

AU - Van Den Abbeele, Annick D.

AU - Berman, Robert M.

AU - Adelstein, S. James

AU - Kassis, Amin I.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The extreme biological toxicity of Auger emitters is caused by the decay-associated, highly localized deposition of energy. The antineoplastic capability of an Auger-electron emitter, iodine-123, incorporated into the thymidine analog, 5-iodo-2′-deoxyuridine (IUdR) was evaluated in an intraperitoneal (ig.) murine ovarian tumor (MOT) in female C3HeB/Fej mice. Total doses of 0.37 to 8.88 MBq (10-240 μCi) 123IUdR were administered i.p. in five equally divided fractions at 24, 28, 32, 36, and 40 hr after the i.p. inoculation of 0.5 to 1.6 × 106 tumor cells per mouse. Control tumor-bearing animals were injected with identical volumes of saline at 4-hr intervals. Biodistribution studies demonstrated a distinct and localized uptake of 123IUdR in the MOT cells (1 % of the injected dose was associated with MOT cells 24 hr after the last injection), whereas in animals without tumor there was no radioactivity associated with the peritoneal cells. Analogous results were obtained from scintigraphic images where the focal area of abdominal activity persisted only in MOT-bearing mice while it cleared from the abdomen of the controls. The 50% survival (median survival) of the control group was 19 days for an inoculum of 1.6 × 106 MOT cells per animal, whereas the median survival of MOT-bearing animals treated with 123IUdR increased by 11 days for the highest administered dose (8.88 MBq, 240 μCi) and resulted in a 20% absolute survival at 7 weeks. Statistically significant absolute survival prolongation was found with all of the total administered doses. The prolongation of both median and absolute survival time of the tumor-bearing animals treated with 123IUdR conclusively indicates the substantial antineoplastic activity of the Auger-electron emitter iodine-123.

AB - The extreme biological toxicity of Auger emitters is caused by the decay-associated, highly localized deposition of energy. The antineoplastic capability of an Auger-electron emitter, iodine-123, incorporated into the thymidine analog, 5-iodo-2′-deoxyuridine (IUdR) was evaluated in an intraperitoneal (ig.) murine ovarian tumor (MOT) in female C3HeB/Fej mice. Total doses of 0.37 to 8.88 MBq (10-240 μCi) 123IUdR were administered i.p. in five equally divided fractions at 24, 28, 32, 36, and 40 hr after the i.p. inoculation of 0.5 to 1.6 × 106 tumor cells per mouse. Control tumor-bearing animals were injected with identical volumes of saline at 4-hr intervals. Biodistribution studies demonstrated a distinct and localized uptake of 123IUdR in the MOT cells (1 % of the injected dose was associated with MOT cells 24 hr after the last injection), whereas in animals without tumor there was no radioactivity associated with the peritoneal cells. Analogous results were obtained from scintigraphic images where the focal area of abdominal activity persisted only in MOT-bearing mice while it cleared from the abdomen of the controls. The 50% survival (median survival) of the control group was 19 days for an inoculum of 1.6 × 106 MOT cells per animal, whereas the median survival of MOT-bearing animals treated with 123IUdR increased by 11 days for the highest administered dose (8.88 MBq, 240 μCi) and resulted in a 20% absolute survival at 7 weeks. Statistically significant absolute survival prolongation was found with all of the total administered doses. The prolongation of both median and absolute survival time of the tumor-bearing animals treated with 123IUdR conclusively indicates the substantial antineoplastic activity of the Auger-electron emitter iodine-123.

KW - 5-Iodo-2′-deoxyuridine

KW - Auger-electron emitters

KW - Biodistribution

KW - Dosimetry

KW - Iodine radioisotopes

KW - Murine ovarian tumor

KW - Radiotherapy

KW - Scintigraphy

UR - http://www.scopus.com/inward/record.url?scp=0025919743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025919743&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(91)90331-W

DO - 10.1016/0360-3016(91)90331-W

M3 - Article

VL - 21

SP - 1541

EP - 1551

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 6

ER -